Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

SUPporting high quality evaluation of COVID-19 convalescent Plasma thrOughoutT Europe

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

D3.4 Dashboard report (se abrirá en una nueva ventana)

Dashboard report

Final recommendations for CCP use to treat COVID-19 (se abrirá en una nueva ventana)
D2.7 Assessment report on data quality and number of complete datasets (se abrirá en una nueva ventana)

Assessment report on data quality and number of complete datasets

D7.1 Composition of the Scientific and Ethics Advisory Board (se abrirá en una nueva ventana)

Composition of the Scientific and Ethics Advisory Board.

D2.6 Status report: SUPPORT-E funding of clinical trials in need. (se abrirá en una nueva ventana)

Status report SUPPORTE funding of clinical trials in need

D1.1 Status report of EU and International ongoing/upcoming clinical trials (se abrirá en una nueva ventana)

Status report of EU and International ongoing/upcoming clinical trials.

D2.13 Assessment report on data quality and number of complete datasets (se abrirá en una nueva ventana)

Assessment report on data quality and number of complete datasets

D1.4 Status report of international ongoing clinical trials (se abrirá en una nueva ventana)

Status report of international ongoing clinical trials.

D2.12 Status report: SUPPORT-E funding of clinical trials in need (se abrirá en una nueva ventana)

Status report SUPPORTE funding of clinical trials in need

Final Dissemination and Exploitation Plan (video, press release, webpage update and management (se abrirá en una nueva ventana)

Final Dissemination and Exploitation Plan deliverable.

D7.3 Ethics review final report (se abrirá en una nueva ventana)

Ethics review final report

D2.9 Status report: SUPPORT-E funding of clinical trials in need (se abrirá en una nueva ventana)

Status report SUPPORTE funding of clinical trials in need

D1.3 Preliminary guidance document for monitored access (se abrirá en una nueva ventana)

Preliminary guidance document for monitored access.

D2.15 Status report: SUPPORT-E funding of clinical trials in need. (se abrirá en una nueva ventana)

Status report: SUPPORT-E funding of clinical trials in need.

D6.6 Technical report for laypersons (se abrirá en una nueva ventana)

Technical report for laypersons.A technical report (final) for laypersons (brochure) will be produced in order to describe the partners’ conclusions and achievements highlighting the methodology used and describing the recommended implementation process among EU Member States.

D4.4 Standardized quantitative and qualitative results on antibody content of all individual plasmas administered in hospitals linked to participating EBA members (se abrirá en una nueva ventana)

Standardized quantitative and qualitative results on antibody content of all individual plasmas administered in hospitals linked to participating EBA members

D7.2 Ethics review mid report (se abrirá en una nueva ventana)

Ethics review mid report.

D5.2 Recommendations report (se abrirá en una nueva ventana)

Interim Report and recommendations

Assessment report on data quality and number of complete datasets in EU CCP database (se abrirá en una nueva ventana)

Assessment report

D2.2 Status report: SUPPORT-E funding of clinical trials in need (se abrirá en una nueva ventana)

Status report SUPPORTE funding of clinical trials in need

D5.3 Final Recommendations Report (se abrirá en una nueva ventana)

Interim report and recommendations.

D4.2 Access to tests that qualify CP for clinical studies across Europe is assured for BE in need (se abrirá en una nueva ventana)

Access to tests that qualify CP for clinical studies across Europe is assured for BE in need.

D7.4 Ethics review final report (se abrirá en una nueva ventana)

Ethics review final report.

D2.8 Status report: interactions with supported clinical trials and monitored access programmes (se abrirá en una nueva ventana)

Status report interactions with supported clinical trials and monitored access programmes

D2.11 Status report: interactions with supported clinical trials and monitored access programmes (se abrirá en una nueva ventana)

Status report interactions with supported clinical trials and monitored access programmes

D1.6 Status report of international ongoing clinical trials (se abrirá en una nueva ventana)

Status report of international ongoing clinical trials

D2.18 Update on clinical trial COVIC-19: patient enrolment and patient characteristics, viral variants and CCP products (se abrirá en una nueva ventana)

Technical update deliverable

D2.14 Analysis report on database data and novel generated data (se abrirá en una nueva ventana)

Analysis report on database data and novel generated data

Quality Assessment and Standardization of Multiple SARS-CoV-2 Serological Assays in Superimmunized Individuals. (se abrirá en una nueva ventana)
D2.4 Status report: interactions with supported clinical trials and monitored access programmes (se abrirá en una nueva ventana)

Status report interactions with supported clinical trials and monitored access programmes

D4.1 Variability between tests across Europe mapped so standardization and calibration possible (se abrirá en una nueva ventana)

Variability between tests across Europe mapped so standardization and calibration possible .

D1.5 Status report of international ongoing clinical trials (se abrirá en una nueva ventana)

Status report of international ongoing clinical trials.

D2.1 Status report: interactions with supported clinical trials and monitored access programmes (se abrirá en una nueva ventana)

Status report interactions with supported clinical trials and monitored access programmes

D2.10 Assessment report on data quality and number of complete datasets (se abrirá en una nueva ventana)

Assessment report on data quality and number of complete datasets

D2.16 Update on clinical trial COVIC-19: patient enrolment and patient characteristics, viral variants and CCP products (se abrirá en una nueva ventana)

Technical update deliverable

D4.3 PoC of test measuring in vitro virus neutralizing activity on ELISA basis (se abrirá en una nueva ventana)

PoC of test measuring in vitro virus neutralizing activity on ELISA basis.

D5.1 Recommendations report (se abrirá en una nueva ventana)

Interim report and recommendations

D3.1 Dashboard report (se abrirá en una nueva ventana)

Dashboard report.

D6.4 Technical report for laypersons (se abrirá en una nueva ventana)

Technical report for laypersons.A technical report (interim) for laypersons (brochure) will be produced in order to describe the partners’ conclusions and achievements highlighting the methodology used and describing the recommended implementation process among EU Member States

D2.5 Status report: interactions with supported clinical trials and monitored access programmes (se abrirá en una nueva ventana)

Status report interactions with supported clinical trials and monitored access programmes

D2.3 Assessment report on data quality and number of complete datasets (se abrirá en una nueva ventana)

Assessment report on data quality and number of complete datasets

D1.2 Preliminary guidance document with assessment criteria for clinical trials (se abrirá en una nueva ventana)

Preliminary guidance document with assessment criteria for clinical trials.

D3.2 Data analysis report and statistical power calculations (se abrirá en una nueva ventana)

Data analysis report and statistical power calculations

Interim Analysis of the data from the EU CCP database (se abrirá en una nueva ventana)

This deliverable will analyze the datasets provided by the clinical study.

D2.19 Update on clinical trial COVIC-19: patient enrolment and patient characteristics, viral variants and CCP products (se abrirá en una nueva ventana)

Technical update deliverable

D6.7 Technical Report for laypersons (se abrirá en una nueva ventana)

Technical Report for laypersons deliverable.

Publicaciones

Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors (se abrirá en una nueva ventana)

Autores: Bernd Jahrsdörfer, Rüdiger Groß, Alina Seidel, Lukas Wettstein, Carolin Ludwig, Tatjana Schwarz, Sixten Körper, Markus Rojewski, Ramin Lotfi, Christoph Weinstock, Erhard Seifried, Victor Max Corman, Christian Drosten, Jan Münch, Hubert Schrezenmeier
Publicado en: The Journal of Immunology, Edición 206/11, 2021, Página(s) 2614-2622, ISSN 0022-1767
Editor: American Association of Immunologists
DOI: 10.4049/jimmunol.2100036

BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. (se abrirá en una nueva ventana)

Autores: Jahrsdörfer B, Proffen M, Scholz J, Hägele J, Ludwig C, Vieweg C, Grempels A, Fabricius D, Lotfi R, Körper S, Adler G, Schrezenmeier H.
Publicado en: Frontiers in Immunology, 2022, ISSN 1664-3224
Editor: Lausanne: Frontiers Media S.A., 2010-
DOI: 10.3389/fimmu.2022.920210

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial (se abrirá en una nueva ventana)

Autores: Simone Hoffmann1*, Eva Schrezenmeier2*, Maxime Desmarets3,4, Fabian Halleck2, Antoine Durrbach5,6, Lynn Peters7, Anna-Teresa Tremmel8, Alina Seidel9, Marita Führer1, Friederike Bachmann2, Jens Schrezenmeier10, Jochen Greiner11, Sixten Körper1, Henrike Hofmann1, Carolin Ludwig1, Christiane Vieweg1, Bernd Jahrsdörfer1, Klemens Budde2, Michael Schmidt12, Jan Münch9, Nizar Joher5, Etienne Dagui
Publicado en: eBioMedicine (a Lancet Health Science journal), Edición 105653, 2025, ISSN 2352-3964
Editor: Elsevier BV
DOI: 10.1016/j.ebiom.2025.105613

B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab (se abrirá en una nueva ventana)

Autores: Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, Kotsch K, Chen Y, Claußnitzer A, Haibel H, Proft F, Guerra G, Durek P, Heinrich F, Ferreira-Gomes M, Burmester GR, Radbruch A, Mashreghi MF, Lino AC, Dörner T.
Publicado en: Arthritis Rheumatol, 2022, ISSN 2326-5191
Editor: Arthritis Rheumatol
DOI: 10.1002/art.42060

B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients (se abrirá en una nueva ventana)

Autores: Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Chen Y, Jahrsdörfer B, Ludwig C, Schrezenmeier H, Lino AC, Dörner T
Publicado en: Frontier of Immunology, 2022, ISSN 1664-3224
Editor: Lausanne: Frontiers Media S.A., 2010-
DOI: 10.3389/fimmu.2022.822885

B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients (se abrirá en una nueva ventana)

Autores: Schrezenmeier E, Rincon-Arevalo H, Stefanski AL, Potekhin A, Straub-Hohenbleicher H, Choi M, Bachmann F, Pross V, Hammett C, Schrezenmeier H, Ludwig C, Jahrsdörfer B, Lino A, Eckardt KU, Kotsch K, Dörner T, Budde K, Sattler A, Halleck F
Publicado en: J Am Soc Nephrol, 2021, ISSN 1533-3450
Editor: Journal of the American Society of Nephrology
DOI: 10.1681/asn.2021070966

A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma. (se abrirá en una nueva ventana)

Autores: Elise Wouters; Caro Verbrugghe; Rosalie Devloo; Isabelle Debruyne; Dorien De Clippel; Leen Van Heddegem; Kristin Van Asch; Véronique Van Gaver; Miek Vanbrabant; An Muylaert; Veerle Compernolle; Hendrik B. Feys
Publicado en: TRANSFUSION, Edición 2, 2021, ISSN 0041-1132
Editor: Blackwell Publishing Inc.
DOI: 10.1111/trf.16652

Hyperimmune immunoglobulin for people with COVID‐19 (se abrirá en una nueva ventana)

Autores: Kimber C, Valk SJ, Chai KL, Piechotta V, Iannizzi C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N.
Publicado en: The Cochrane Database of Systematic Reviews, 2023, Página(s) CD015167, ISSN 1465-1858
Editor: The Cochrane Database of Systematic Reviews
DOI: 10.1002/14651858.cd015167.pub2

Effects of SARS-CoV-2 strain variation on virus neutralisation titres: therapeutic use of convalescent plasma. (se abrirá en una nueva ventana)

Autores: Dung Nguyen; Julie Xiao; Peter Simmonds; Abigail Lamikanra; Valerie Odon; Jeremy Ratcliff; Alain Townsend; Alain Townsend; David J. Roberts; David J. Roberts; H. Harvala; H. Harvala
Publicado en: The journal of infectious diseases, Edición 2, 2021, ISSN 1537-6613
Editor: The journal of infectious diseases.
DOI: 10.1093/infdis/jiab563

Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. (se abrirá en una nueva ventana)

Autores: Schrezenmeier E, Rincon-Arevalo H, Jens A, Stefanski AL, Hammett C, Osmanodja B, Koch N, Zukunft B, Beck J, Oellerich M, Proß V, Stahl C, Choi M, Bachmann F, Liefeldt L, Glander P, Schütz E, Bornemann-Kolatzki K, López Del Moral C, Schrezenmeier H, Ludwig C, Jahrsdörfer B, Eckardt KU, Lachmann N, Kotsch K, Dörner T, Halleck F, Sattler A, Budde K.
Publicado en: JCI Insight, 2022, ISSN 2379-3708
Editor: JCI Insight
DOI: 10.1172/jci.insight.157836

Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary (se abrirá en una nueva ventana)

Autores: Elise Wouters, Maurice Steenhuis, Hubert Schrezenmeier, Pierre Tiberghien, Heli Harvala, Hendrik B. Feys, Ellen Schoot
Publicado en: Vox Sanguinis, Edición 116/5, 2021, Página(s) 493-496, ISSN 0042-9007
Editor: Blackwell Publishing Inc.
DOI: 10.1111/vox.13060

Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors (se abrirá en una nueva ventana)

Autores: Steenhuis, Maurice; van Mierlo, Gerard; Derksen, Ninotska Il; Ooijevaar-de Heer, Pleuni; Kruithof, Simone; Loeff, Floris L; Berkhout, Lea C; Linty, Federica; Reusken, Chantal; Reimerink, Johan; Hogema, Boris; Zaaijer, Hans; van de Watering, Leo; Swaneveld, Francis; van Gils, Marit J; Bosch, Berend Jan; van Ham, S Marieke; Ten Brinke, Anja; Vidarsson, Gestur; van der Schoot, Ellen C; Rispens, Theo;
Publicado en: VOLUME=10;ISSUE=5;TITLE=Clinical & translational immunology, Edición 2, 2021, ISSN 2050-0068
Editor: John Wiley & Sons Australia, Ltd
DOI: 10.1002/cti2.1285

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients (se abrirá en una nueva ventana)

Autores: Arne Sattler, Eva Schrezenmeier, Ulrike A. Weber, Alexander Potekhin, Friederike Bachmann, Henriette Straub-Hohenbleicher, Klemens Budde, Elena Storz, Vanessa Proß, Yasmin Bergmann, Linda M.L. Thole, Caroline Tizian, Oliver Hölsken, Andreas Diefenbach, Hubert Schrezenmeier, Bernd Jahrsdörfer, Tomasz Zemojtel, Katharina Jechow, Christian Conrad, Sören Lukassen, Diana Stauch, Nils Lachmann, Mira
Publicado en: Journal of Clinical Investigation, Edición 131/14, 2021, ISSN 1558-8238
Editor: American Society for Clinical Investigation
DOI: 10.1172/jci150175

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data (se abrirá en una nueva ventana)

Autores: Dung Nguyen, Peter Simmonds, Maurice Steenhuis, Elise Wouters, Daniel Desmecht, Mutien Garigliany, Marta Romano, Cyril Barbezange, Piet Maes, Bram Van Holm, Joaquín Mendoza, Salvador Oyonarte, Anders Fomsgaard, Ria Lassaunière, Eva Zusinaite, Katarina Resman Rus, Tatjana Avšič-Županc, Johan HJ Reimerink, Fiona Brouwer, Marieke Hoogerwerf, Chantal BEM Reusken, Gunnveig Grodeland, Sophie Le Cam
Publicado en: Eurosurveillance, Edición 26/27, 2021, ISSN 1560-7917
Editor: European Center for Disease Prevention and Control
DOI: 10.2807/1560-7917.es.2021.26.27.2100568

Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization (se abrirá en una nueva ventana)

Autores: Heli Harvala; Dung Nguyen; Peter Simmonds; Abigail A. Lamikanra; Hoi Pat Tsang; Ashley Otter; Piet Maes; Mhairi Webster; Adam Clarkson; Fotini Kaloyirou; Valerie Hopkins; Stephen M. Laidlaw; Miles Carroll; Ana Mora; Alexandra Griffiths; Sheila MacLennan; Lise Estcourt; David J. Roberts
Publicado en: Transfusion, Edición 1, 2022, ISSN 0041-1132
Editor: Blackwell Publishing Inc.
DOI: 10.1111/trf.16934

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents (se abrirá en una nueva ventana)

Autores: Jahrsdörfer B, Fabricius D, Scholz J, Ludwig C, Grempels A, Lotfi R, Körper S, Adler G, Schrezenmeier H
Publicado en: Front Immunol, 2021, ISSN 1664-3224
Editor: Lausanne: Frontiers Media S.A., 2010-
DOI: 10.3389/fimmu.2021.743422

A novel competition ELISA for the selection of COVID-19 convalescent plasma donors

Autores: Verbrugghe, C; Wouters, E; Compernolle, V; Feys, H.B.
Publicado en: 2021
Editor: Ghent University Press

Buscando datos de OpenAIRE...

Se ha producido un error en la búsqueda de datos de OpenAIRE

No hay resultados disponibles

Mi folleto 0 0